Our history

From a distinguished pharmacy to a global leader in the aesthetic medicine sector

1985

Employees 150

Official distributors 90

International sales 85%

Annual R&D+i budget 45%

Countries 90

m2 of facilities in Barcelona 9500

The company has been committed to the development and marketing of top-quality products right from the start, with scientifically proven results.

Our progress is linked to ongoing research and collaboration with hospitals, universities and experienced specialists from the sector as the company works closely with these to research and develop new treatments.

Story

1990 - 1999
Development of a wider portfolio and expansion to international trade

Ongoing collaboration with the medical sector has enabled mesoestetic to develop numerous innovative products to treat other aesthetic problems associated with signs and symptoms of aging and figure concerns.

The results and effectiveness of these products are known worldwide as the company now markets its products in more than 50 countries through distributors and renowned aesthetics professionals.

Cosmelan

2002
World-leading treatment for pigmented blemishes: cosmelan®

mesoestetic® is the world leader in the treatment of hyperpigmentation after reformulating one of our most successful products with the launch of cosmelan®.

2010
mesohyal®: customizable anti-aging solutions

Global innovation with the widest range of injectable medical devices with CE marking for intradermal aesthetic injections.

The company is at the forefront of aesthetic medicine, offering a range of products to treat a variety of aging-related problems in a customized, targeted manner.

2011 - 2014
New Headquarters with Biotechnology Unit and Medical Unit

Our current facilities, covering over 8,500 m2, which were opened in 2011, are proof of our commitment to growth and excellence.

Our new headquarters are home to our production lines (cosmeceuticals, nutraceuticals, medications and injectable medical devices) and our Biotechnology Unit and Medical Unit for Observational Control and Surveillance, which give us the ability to research even more effective active ingredients and conduct in vitro and in vivo testing on the state-of-the-art products we manufacture.

The company exports more than 85% of sales, and our products and treatments are available in more than 80 countries across all continents.

2015
First topical medication: anestopic®

In 2015, the company obtained authorization from the Spanish Agency of Medicines and Medical Devices (Agencia Española del Medicamento y Producto Sanitario) to manufacture and market its first-ever medication. 

Anestopic® is a local anesthetic cream for topical application designed to temporarily numb areas of the body prior to certain dermatological and aesthetic procedures.

2017
mesofiller®: last generation of filling products

After four years of research and development, mesoestetic® presents two references of dermal implants based on cross-linked hyaluronic acid of very high quality for correcting wrinkles and restoring facial volume. mesofiller global and mesofiller intense are fully integrated in the wide medical range of mesoestetic®, allowing to perform combined and customised treatments to meet each patient’s needs.

2017
Genesis: the first device with the exclusive SmartDrivity® technology

For the purpose of continuing to provide professionals with the most cutting-edge technology and the most effective treatments, mesoestetic® has developed Genesis, the first medical-aesthetic device that is based on SmartDrivity™ technology. Thanks to the smart merging of 4 technologies, together with the pharmacological effect of the exclusive products, Genesis offers a wide range of programmes which allow to create 100% customised treatments, with an excellent therapeutic response level.

2018
Second medical speciality: melanoderm®

mesoestetic®, as a specialist in the development of depigmenting solutions, presents melanoderm®, a highly-effective specific medical treatment that represents a therapeutic option for the treatment of skin hyperpigmentations.melanoderm® means a further step in the company positioning as world leader in depigmentation, in addition to continue innovating in the medical field to provide professionals with treatments with a high efficacy, safety and tolerance to ensure maximum patient satisfaction.

2018
Purchase of new plots and extension of the corporate headquarters

After years of success and corporate growth, and expecting to continue maintaining the current pace, mesoestetic® acquired the plot adjacent to its facilities to extend its corporate headquarters. The new building will be built to both meet the R&D&I needs of the laboratory and offer the best and most comprehensive training for its partners and customers.

2019
Investment in a new intralogistic centre

mesoestetic® extends again its corporate headquarters with the acquisition of a site of over 3000 m2, adjacent to its facilities in Viladecans. The site will host a new intralogistic project, designed to improve its efficiency, that will optimise 100% the company’s storage operations and 35% its picking operations. This project is within the framework of the international expansion and growth strategic plan of the company to continue offering in the market the best service and the most innovative products.

2020
New category: aesthetic gynaecology

mesoestetic® extends its portfolio at the service of gynaeco-aesthetics with the aim of offering, mainly to women, treatments for integral body care. Through the recovery of genital harmony, the company intends to contribute to improving sexual health in women, positively impacting their self-esteem and quality of life. In reply to a real market need and developed in collaboration with worldwide benchmarks in this field, mesoestetic® presents dermamelan® intimate, the medical treatment created specifically to remove hyperpigmentation in the intimate area. This is the first commitment of mesoestetic® to the intimate category, and gathers all the company’s knowledge in depigmentation, an area in which it is the world leader. dermamelan® intimate is the starting point for a global strategy of mesoestetic®, that will shortly introduce novelties for intimate rejuvenation in women.

2020
New mesohyal™: cellular treatment based on biomimetic peptides

mesoestetic® presents a big innovation in intradermal facial treatment by adding two new formulations based on biomimetic peptides, a new generation of highly-effective active ingredients with a high specificity that act on the biological processes that can reverse skin cell aging.For the purpose of meeting the growing demand for this type of devices, mesohyal™ by mesoestetic® becomes established as the broadest range of intradermal solutions, with CE marking, for a customised cellular treatment.

Leave the professional area Leave the exclusive area of professionals and access the web for consumers